Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors. Sub-study to Characterize the Effects of Tinostamustine at a Dose of 60mg/m2 Administered During a 60 Minutes Infusion on Cardiac Repolarization, in Patients With Advanced Solid Tumors. Sub-study to Characterize the Effects of Tinostamustine at a Dose of 80mg/m2 Administered During a 80 Minutes Infusion on Cardiac Repolarization, in Patients With Advanced Solid Tumors.
Conditions
Interventions
Tinostamustine 60mg/m2 over 30min
Tinostamustine 80mg/m2 over 30min
+5 more
Locations
13
United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Stanford University Medical Center
Palo Alto, California, United States
University of Michigan
Ann Arbor, Michigan, United States
New York University
New York, New York, United States
Mary Crowley Cancer Research
Dallas, Texas, United States
Juravinski Cancer Centre
Hamilton, Ontario, on, Canada
Start Date
November 8, 2017
Primary Completion Date
July 27, 2022
Completion Date
March 29, 2023
Last Updated
October 21, 2024
NCT07177937
NCT06043817
NCT05671510
NCT06393374
NCT06422806
NCT06257264
Lead Sponsor
Mundipharma Research Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions